PATENT CLAIM ANALYSIS

Application Number: 15956385
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "499000"]

Abstract:
The disclosure provides a sustained release injectable neurosteroid formulation comprising neurosteroid particles having a D50 of less than 10 microns, the neurosteroid particles comprising a neurosteroid of Formula I: or a pharmaceutically acceptable salt thereof, wherein:   is a double or single bond and the variables, e.g., R 1 , R 2 , R 3 , R 4 , R 4a , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 10a  are described herein. The formulation comprises neurosteroid particles comprising the neurosteroid and a polymeric surface stabilizer and provides an effective plasma concentration of the neurosteroid at steady state for at least 48 hours, and in some embodiments for at least 4 weeks. The sustained release injectable neurosteroid formulation can formulated for intramuscular or subcutaneous administration. The disclosure provides a method of treating a patient having seizures, anxiety, agitation, depression (including post-partum depression), schizophrenia, post-traumatic stress disorder, or tremors by administering the sustained release neurosteroid formulation to the patient. In certain embodiments the neurosteroid is ganaxolone.

Claim (Index 2):
The sustained release injectable neurosteroid formulation of  claim 1 , wherein\n R 1  is a group of the formula each instance of R A , R B , and R C  is, independently, hydrogen, halogen, \u2014NO 2 , \u2014CN, \u2014OR GA , \u2014N(R GA ) 2 , \u2014C(\u2550O)R GA , \u2014C(\u2550O)OR GA , \u2014OC(\u2550O)R GA , \u2014OC(\u2550O)OR GA , \u2014C(\u2550O)N(R GA ) 2 , \u2014N(R GA )C(\u2550O)R GA , \u2014OC(\u2550O)N(R GA ) 2 , \u2014N(R GA )C(\u2550O)OR GA , \u2014N(R GA )C(\u2550O)N(R GA ) 2 , \u2014SR GA , \u2014S(O)R GA , e.g., \u2014S(\u2550O)R GA , \u2014S(\u2550O) 2 R GA , \u2014S(\u2550O) 2 OR GA , \u2014OS(\u2550O) 2 R GA , \u2014S(\u2550O) 2 N(R GA ) 2 , \u2014N(R GA )S(\u2550O) 2 R GA , optionally substituted alkyl, optionally substituted C 3 -C 6  carbocyclyl, or optionally substituted 3- to 6-membered heterocyclyl; and where instance of R GA  is independently hydrogen, optionally substituted alkyl, optionally substituted C 3 -C 6  carbocyclyl, optionally substituted 3- to 6-membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to oxygen, nitrogen protecting group when attached to nitrogen, or two R GA  groups are taken with the intervening atoms to form a substituted or unsubstituted heterocyclyl or heteroaryl ring.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 91.0
- Lexical Diversity: 2.0102
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15700314', '14772726', '11587906', '12041038', '12320539']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7208822224342901
- 35 USC 102 Novelty (BERT): 0.5067016372349746
- Combined Prediction Score: 0.6994641639143585
- Mean Citation Score: 207.997362
- Max Citation Score: 269.98532
- Similarity Product: 198.4496097390652

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test